糖尿病黄斑浮腫に対するベバシズマブ硝子体内投与の治療経過

Outcome of intravitreal injection of bevacizumab for diabetic macular edema

要約　目的：糖尿病黄斑浮腫に対するベバシズマブ硝子体内投与の成績の報告。対象と方法：糖尿病黄斑浮腫に対してベバシズマブを硝子体内に投与した11例11眼を対象とした。全例に硝子体手術の既往はなく，術後3か月間の視力と中心窩厚を検索した。視力はlogMARで評価した。結果：投与前の中心窩厚は平均438±107μmで，術後3か月間に有意差がなかった。平均視力は術後1か月までは変化がなく，3か月後に1眼で0.2以上に改善し，10眼で不変であった。ベバシズマブの再注入は6眼で行われ，中心窩厚が300μm以下の2眼ではこれを必要としなかった。結論：糖尿病黄斑浮腫に対するベバシズマブの硝子体内注入では，3か月間の観察で視力と中心窩厚に有意な変化がなかった。黄斑浮腫が軽度な症例にはこれが有効である可能性がある。

Abstract.　Purpose：To report the outcome of intravitreal injection of bevacizumab for diabetic macular edema. Cases and Method：This retrospective study was made on 11 eyes of 11 cases that received bevacizumab for diabetic macular edema. All the eyes had no history of vitreous surgery. Cases were followed up for 3 months after treatment. Visual acuity was evaluated as logMAR. Results：Foveal thickness averaged 438±107μm initially and showed no significant changes for 3 months after treatment. Averaged visual acuity remained the same for one month after treatment. It improved by 2 lines or more in one eye and remained the same in 10 eyes three months after treatment. Treatment was repeated in 6 eyes. It was not needed in 2 eyes that had foveal thickness of less than 300μm. Conclusion：Intravitreal injection of bevacizumab induced no significant changes in visual acuity or foveal thickness in eyes with diabetic macular edema. There is a possibility that this modality may be effective for eyes with less severe macular edema.